Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagiwara, Satoru, Watanabe, Tomohiro, Kudo, Masatoshi, Minaga, Kosuke, Komeda, Yoriaki, Kamata, Ken, Kimura, Masatomo, Hayashi, Hidetoshi, Nakagawa, Kazuhiko, Ueshima, Kazuomi, Minami, Yasunori, Aoki, Tomoko, Takita, Masahiro, Morita, Masahiro, Cishina, Hirokazu, Ida, Hiroshi, Park, Ah-Mee, Nishida, Naoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085223/
https://www.ncbi.nlm.nih.gov/pubmed/33927311
http://dx.doi.org/10.1038/s41598-021-88824-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085223/
https://www.ncbi.nlm.nih.gov/pubmed/33927311
http://dx.doi.org/10.1038/s41598-021-88824-1

Ejemplares similares